Psilocybin
→Adverse events

3

1

2

↑3

↓1

—2

Evidence suggests Psilocybin mayincreaseAdverse events.

5 studies (6 claims)

Emerging evidence

Typical effective dose 25 (25–25) mgacross 2 dosed studies

Study Claims

6 of 6

Intervention	Direction	Endpoint	Type	Population	Dosage	Title
psilocybin therapy	No effect - no serious adverse events	serious adverse events	Human	people with mild to moderate stage PD plus depression and/or anxiety	One 10 mg dose followed by one 25 mg dose, administered with psychotherapy.	Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial.
psilocybin therapy	Increases - experienced treatment-emergent adverse events	treatment-emergent adverse events	Human	people with mild to moderate stage PD plus depression and/or anxiety	One 10 mg dose followed by one 25 mg dose, administered with psychotherapy.	Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial.
psilocybin-assisted psychotherapy	No effect - revealing variations in measuring, reporting methods and occurrences	physical and psychological adverse events during and after psilocybin sessions	Human	clinical populations	Heterogeneous doses (specific amounts not detailed in the abstract).	The safety of psilocybin-assisted psychotherapy: A systematic review.cited 1×
psilocybin	Increases - associated with a higher risk	adverse events	Human	adult patients with MDD	25 mg, 0.215 mg/kg, and 10 mg.	Efficacy and safety of psilocybin in the treatment of Major Depressive Disorder (MDD): A dose-response network meta-analysis of randomized placebo-controlled clinical trials.cited 2×
psilocybin	Decreases - discouraged participation	adverse events associated with psilocybin	Human	patients with chronic neuropathic pain	Not mentioned	Prospective Preference Assessment for the Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN (PEACE-PAIN) Trial.cited 1×
psilocybin	Increases - instigated	prolonged adverse events	Human	a participant in a phase 2b clinical trial of psilocybin for treatment-resistant depression	Not specified	Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: case report and thematic analysis of one participant's experience.cited 1×